NasdaqGS:PCRXPharmaceuticals
Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist Pressure - Has The Bull Case Changed?
Pacira BioSciences recently reported preliminary unaudited 2025 revenue of US$726.4 million, modestly above the prior year’s US$701.0 million, while also completing a US$150.05 million buyback totaling 5,932,106 shares since May 2025.
At the same time, the company lowered its 2025 revenue forecast and faced fresh pressure from activist DOMA Perpetual Capital Management, which is pushing for board changes and a potential sale process.
Next, we’ll examine how the downward 2025 revenue forecast...